Glenmark Pharmaceuticals announced that it will now directly commercialize and distribute Ryaltris olopatadine / mometasone nasal spray in the US. Hikma acquired US rights to Ryaltris in February 2020 and launched the nasal spray in the US in August 2022 following FDA approval of Ryaltris for the treatment of seasonal allergic rhinitis in January 2022.
In addition to the US, Ryaltris has been approved in Canada, the EU and UK, Australia, Russia, Korea, and China. According to the company, the nasal spray is currently marketed in 55 countries. The FDA recently approved another Glenmark inhalation product, a generic equivalent of GSK’s FloVent HFA fluticasone propionate MDI, and the company said that it would launch that inhaler in the US.
Glenmark President and Business Head, North America, Marc Kikuchi commented, “The commercialization by Glenmark for Ryaltris in the United States is an important step forward for the growth of our company. It allows us greater operational direction in how we engage the market and support healthcare providers and patients across the nation. Today’s announcement also marks a significant moment in our broader effort to strengthen our innovative businesses in the US and build a more direct, sustainable commercial presence over time.”
Read the Glenmark Pharmaceuticals press release
